Bg pattern

CLAVERSAL ESPUMA RECTAL (Rectal Foam)

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use CLAVERSAL ESPUMA RECTAL (Rectal Foam)

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Patient Information Leaflet

Claversal 1 g Rectal Foam

mesalazine

Read this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others, as it may harm them, even if their symptoms are the same as yours.
  • If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What is Claversal rectal foam and what is it used for
  2. What you need to know before you start using Claversal rectal foam
  3. How to use Claversal rectal foam
  4. Possible side effects
  5. Storage of Claversal rectal foam
  6. Contents of the pack and further information

1. What is Claversal rectal foam and what is it used for

Claversal contains mesalazine (also known as 5-aminosalicylic acid), which belongs to a group of medicines called intestinal anti-inflammatory agents.

Claversal rectal foam is indicated for the treatment of ulcerative colitis, an inflammatory disease of the intestine.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you start using Claversal rectal foam

Do not use Claversal

  • if you are allergic to mesalazine or any of the other ingredients of this medicine (listed in section 6)
  • if you are allergic to acetylsalicylic acid or any other salicylate
  • if you have a medical condition that may make you prone to bleeding
  • if you have severe kidney and/or liver impairment

Warnings and precautions

Talk to your doctor or pharmacist before you start using Claversal

  • if you are or plan to become pregnant
  • if you are breast-feeding
  • if you have liver or kidney problems
  • if you have any lung disease, such as asthma
  • if you have been allergic to sulfasalazine in the past
  • if you have a stomach or intestinal ulcer
  • if you have previously had inflammation of the heart (which could be a consequence of a heart infection)
  • if you have ever had a severe skin rash, blistering, or peeling after using mesalazine.

If you experience severe headache or recurrent headache, vision changes, or ringing or buzzing in the ears, contact your doctor immediately.

In case of appearance of any allergic manifestation (e.g., skin rash, itching) or fever during the course of treatment, do not apply more Claversal rectal foam and inform your doctor immediately.

Before and during treatment, your doctor may want to perform regular blood and urine tests to check the functioning of your liver, kidneys, blood, and lungs.

Kidney stones may occur with the use of mesalazine. The symptoms include pain in the sides of the abdomen and blood in the urine. Make sure to drink enough liquid during treatment with mesalazine.

Severe skin rashes, such as drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SSJ), and toxic epidermal necrolysis (TEN), have been observed with mesalazine treatment. Stop taking mesalazine and seek immediate medical attention if you observe any of the symptoms related to these severe skin reactions described in section 4.

Mesalazine may cause a discoloration of the urine to a reddish-brown color after contact with sodium hypochlorite bleach in the toilet water. This is a chemical reaction between mesalazine and bleach and is harmless.

Children and adolescents

The information on safety in the use of this medicine in children and adolescents is limited.

Do not administer to children under 5 years of age.

Other medicines and Claversal rectal foam

In general, you can continue treatment with other medicines while using Claversal. However, inform your doctor or pharmacist if you are using, have recently used, or might use any other medicine, including those bought without a prescription.

Claversal may interact with other medicines if taken at the same time.

In particular:

  • medicines to lower blood sugar (antidiabetics)
  • medicines to lower blood pressure (antihypertensives/diuretics)
  • medicines for the treatment or prevention of gout attacks
  • medicines that help with bowel movements (laxatives containing lactulose)
  • medicines to prevent blood clotting (anticoagulants)
  • medicines to reduce the activity of the immune system (e.g., azathioprine, 6-mercaptopurine, or thioguanine)
  • medicines to treat pain and inflammation (anti-inflammatory agents)

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.

There is limited experience with the use of mesalazine during pregnancy and breast-feeding. The newborn may develop allergic reactions after breast-feeding, such as diarrhea. If the newborn develops diarrhea, breast-feeding should be interrupted.

The use of Claversal is not recommended during pregnancy or breast-feeding unless your doctor advises you otherwise.

Driving and using machines

No adverse effects of Claversal on the ability to drive or use machines have been reported.

Claversal rectal foam containssodium metabisulfite, methyl parahydroxybenzoate, propyl parahydroxybenzoate, and glycerol

This medicine may cause severe allergic reactions and bronchospasm (sudden feeling of suffocation) because it contains sodium metabisulfite.

This medicine may cause allergic reactions (possibly delayed) because it contains methyl parahydroxybenzoate and propyl parahydroxybenzoate.

This medicine may cause a mild laxative effect because it contains glycerol.

This medicine contains less than 23 mg of sodium (1 mmol) per dose; it is essentially sodium-free.

3. How to use Claversal rectal foam

Follow your doctor's instructions for using Claversal exactly, regarding the way and time of using the rectal foam; otherwise, you may not benefit fully from its effects.

In case of doubt, consult your doctor or pharmacist again.

Your doctor will indicate the duration of your treatment with Claversal rectal foam. Do not stop treatment before completion, even if you feel better, as symptoms may return if treatment is stopped too soon.

Strictly follow the treatment according to your doctor's instructions, both in the acute inflammatory phase and in the maintenance time established.

The recommended dose for an adult is:

One to two applications per day (1 to 2 g), for four to six weeks.

Use in children and adolescents

The administration of Claversal to children and adolescents under 18 years of age is not recommended due to the lack of safety and efficacy data.

Do not administer to children under 5 years of age.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

Use in elderly patients

The use of Claversal in elderly patients should be done with caution and limited to those patients with normal renal function.

Claversal 1 g rectal foam is used rectally.

Hands holding and applying a rectal enema with applicator, showing steps of insertion and release of the deviceIf you use more Claversal than you should

Talk to your doctor if you have used more than prescribed. In case of overdose or accidental ingestion, talk to your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount used. It is recommended to take the packaging and the leaflet of the medicine to the healthcare professional.

If you forget to use Claversal

Do not use a double dose to make up for forgotten doses.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

All medicines can cause allergic reactions, although severe allergic reactions are very rare. If you experience any of these symptoms after using this medicine, stop using this medicine and contact your doctor immediately:

  • allergic skin rash;
  • fever;
  • difficulty breathing.

If you experience fever or irritation of the throat or mouth, stop using this medicine and contact your doctor immediately. These symptoms may be due, very rarely, to a decrease in the number of white blood cells in the blood (a condition called agranulocytosis).

Severe side effects:

Stop taking mesalazine and seek immediate medical attention if you experience any of the following symptoms:

  • red patches, or circular or coin-shaped patches on the chest, often with central blisters, skin peeling, ulcers in the mouth, throat, nose, genitals, and eyes, generalized rash, fever, and swollen lymph nodes. These severe skin rashes are often preceded by fever or flu-like symptoms.
  • if you experience severe headache or recurrent headache, vision changes, or ringing or buzzing in the ears. These could be symptoms of increased pressure inside your skull (idiopathic intracranial hypertension)

The following side effects have also been reported in patients using mesalazine:

Rare side effects(may affect up to 1 in 1,000 patients)

  • abdominal pain, diarrhea, flatulence, nausea, and vomiting;
  • headache, dizziness;
  • chest pain, difficulty breathing, or swollen limbs due to an effect on the heart;
  • increased sensitivity of the skin to sunlight and ultraviolet light (photosensitivity)

Very rare side effects(may affect less than 1 in 10,000 patients)

  • kidney problems, sometimes with swollen limbs or side pain;
  • severe abdominal pain due to acute pancreatitis;
  • worsening of colitis symptoms;
  • fever, sore throat, or nausea due to changes in blood count;
  • difficulty breathing, cough, wheezing, spots on lung X-ray due to allergic and/or inflammatory conditions in the lungs;
  • diarrhea and severe abdominal pain due to an allergic reaction to the medicine in the intestine;
  • skin rash or inflammation;
  • muscle and joint pain;
  • jaundice or abdominal pain due to liver or biliary disorders;
  • hair loss and development of baldness;
  • erythema multiforme;
  • numbness and tingling of the fingers and toes (peripheral neuropathy)
  • reversible decrease in semen production;
  • blood count disorders.

Side effects of unknown frequency(cannot be estimated from the available data).

  • kidney stones and associated kidney pain (see also section 2).

Photosensitivity

More severe reactions have been reported in patients with pre-existing skin conditions, such as atopic dermatitis and atopic eczema.

If these symptoms continue or become more severe, talk to your doctor.

Reporting of side effects:

If you experience any side effects, talk to your doctor or pharmacist, even if they are not listed in this leaflet. You can also report them directly through the Spanish Medicines Monitoring System: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Claversal rectal foam

Keep this medicine out of the sight and reach of children.

Do not store above 30°C.

This pack is a pressurized aerosol that contains a flammable propellant. It should be kept away from any heat source, flames, or sparks, including cigarettes. It should be protected from direct sunlight and not destroyed or burned, even when empty.

Do not use this medicine after the expiry date stated on the pack after EXP. The expiry date is the last day of the month indicated.

Medicines should not be disposed of via wastewater or household waste. Place the packaging and any unused medicine in the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.

6. Contents of the pack and further information

Composition of Claversal 1 g rectal foam

  • The active ingredient is mesalazine (1g per application)
  • The other ingredients (excipients) are: sorbitan monooleate, polysorbate 20, emulsifying wax, anhydrous colloidal silica, sodium metabisulfite (E-223), disodium edetate, methyl parahydroxybenzoate (E-218), propyl parahydroxybenzoate (E-216), sodium phosphate dodecahydrate, sodium dihydrogen phosphate dihydrate, glycerol, polyethylene glycol 300, purified water, propane, iso-butane, and n-butane.

Appearance of the product and pack contents

Rectal foam for administration. The foam is white to light brown in color.

The pack includes:

  • 1 aerosol that dispenses 14 applications,
  • a kit consisting of a base or grid with 14 compartments (containing a small amount of petroleum jelly), and 14 disposable applicators are inserted into these compartments. The purpose of the petroleum jelly is to facilitate the introduction of the applicators into the rectum,
  • 14 disposable plastic bags,
  • a patient information leaflet.

Marketing authorization holder

Faes Farma, S.A.

Autonomia Etorbidea, 10

48940 Leioa (Bizkaia)

Spain

Manufacturer

SOFAR

Via Firenze, 40

20060 Trezzano Rosa, Milan

Italy

Date of last revision of this leaflet:January 2025

Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS)http://www.aemps.gob.es/

Online doctors for CLAVERSAL ESPUMA RECTAL (Rectal Foam)

Discuss questions about CLAVERSAL ESPUMA RECTAL (Rectal Foam), including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for CLAVERSAL ESPUMA RECTAL (Rectal Foam)?
CLAVERSAL ESPUMA RECTAL (Rectal Foam) requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in CLAVERSAL ESPUMA RECTAL (Rectal Foam)?
The active ingredient in CLAVERSAL ESPUMA RECTAL (Rectal Foam) is mesalazine. This information helps identify medicines with the same composition but different brand names.
How much does CLAVERSAL ESPUMA RECTAL (Rectal Foam) cost in pharmacies?
The average pharmacy price for CLAVERSAL ESPUMA RECTAL (Rectal Foam) is around 21.76 EUR. Prices may vary depending on the manufacturer and dosage form.
Who manufactures CLAVERSAL ESPUMA RECTAL (Rectal Foam)?
CLAVERSAL ESPUMA RECTAL (Rectal Foam) is manufactured by Faes Farma S.A.. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of CLAVERSAL ESPUMA RECTAL (Rectal Foam) online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether CLAVERSAL ESPUMA RECTAL (Rectal Foam) is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to CLAVERSAL ESPUMA RECTAL (Rectal Foam)?
Other medicines with the same active substance (mesalazine) include ASACOL 1 G SUPPOSITORIES, ASACOL 1600 mg GASTRO-RESISTANT TABLETS, ASACOL 400 mg GASTRO-RESISTANT TABLETS. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media